Nexalin Technology Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Nexalin Technology hat ein Gesamteigenkapital von $2.3M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $2.8M bzw. $507.2K.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$2.14m
Eigenkapital	US$2.33m
Gesamtverbindlichkeiten	US$507.22k
Gesamtvermögen	US$2.83m

Jüngste Berichte zur Finanzlage

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: NXLDie kurzfristigen Aktiva des Unternehmens ($2.6M) übersteigen seine kurzfristigen Passiva ($507.2K).

Langfristige Verbindlichkeiten: NXL hat keine langfristigen Verbindlichkeiten.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: NXL ist schuldenfrei.

Schulden abbauen: NXL hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: NXL verfügt auf der Grundlage des zuletzt gemeldeten freien Cashflows über eine ausreichende Liquiditätsreserve für 8 Monate. [freien Cashflow]], hat aber seitdem zusätzliches Kapital aufgenommen.

Vorhersage Cash Runway: Es wird prognostiziert, dass NXL auf Grundlage der Schätzungen des freien Cashflows über ausreichend Liquidität für 6 Monate verfügt, das Unternehmen hat seitdem jedoch weiteres Kapital aufgenommen.

Nexalin Technology Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Nexalin Technology, Inc. Provides Non-Compliance Update

Nexalin Technology, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology Receives Written Notice from the Nasdaq Listing Qualifications Department Regarding Not Eligible for an Additional 180 Calendar Day Compliance Period

Nexalin Technology, Inc. Receives Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Recent updates

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device

Nexalin Technology, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

Nexalin Technology, Inc. Provides Non-Compliance Update

First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023)

Nexalin Technology, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Nexalin Technology, Inc. has filed a Follow-on Equity Offering in the amount of $5.646485 million.

Nexalin Technology Accelerates Manufacturing of Its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board

Full year 2023 earnings released: US$0.63 loss per share (vs US$0.30 loss in FY 2022)

Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Nexalin Technology, Inc. Unveils Gen-3 HALO™? Clarity 15 Milliamp Neurostimulation Device

Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.026 loss in 3Q 2022)

Nexalin Technology Receives Written Notice from the Nasdaq Listing Qualifications Department Regarding Not Eligible for an Additional 180 Calendar Day Compliance Period

Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal

Nexalin Technology, Inc., Annual General Meeting, Nov 10, 2023

Nexalin Technology, Inc., Annual General Meeting, Nov 10, 2023

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.09 loss in 2Q 2022)

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of Its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

Nexalin Technology, Inc. Receives Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.08 loss in 1Q 2022)

Full year 2022 earnings released: US$0.30 loss per share (vs US$1.43 loss in FY 2021)

Nexalin Technology, Inc. Appoints Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

Insufficient new directors

Third quarter 2022 earnings released: US$0.026 loss per share (vs US$0.40 loss in 3Q 2021)

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million.

Insufficient new directors

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen